New Research Greenlights Popular Obesity Medications for High-Risk Cushing’s Syndrome

Published on August 3, 2026

Popular diabetes and weight-loss medications known as GLP-1 receptor agonists do not increase the risk of cancer in patients with endogenous Cushing’s syndrome, according to a comprehensive nationwide study titled, “GLP-1 Recetor Agonist Exposure and Malignancy Risk in Patients with Endogenous Cushing’s Syndrome,” and published in The Journal of Clinical Endocrinology & Metabolism. The findings […]

The post New Research Greenlights Popular Obesity Medications for High-Risk Cushing’s Syndrome appeared first on Endocrine News.

Continue reading on website
Other news

CMS Releases Annual Physician Payment Proposed Rule; Physician Payment Reform Legislation Introduced in the House 

July 31, 2026
On July 14, the Centers for Medicare & Medicaid Services (CMS) released the CY 2027 Medicare Physician Fee Schedule (MPFS) proposed rule. Below are some specific areas of interest for endocrinologists, which we will comment on:  CMS has posted a fact sheet on the rule on their website. We will provide Endocrine Society members with an in-depth analysis of the rule on our website in August. Every [

VIDEO: Testosterone Alone is Not a Replacement for Lifestyle Changes in Older Men at Risk of Type 2 Diabetes

August 5, 2026
Testosterone treatment may improve body composition, glucose metabolism and sexual desire in some older men at high risk of type 2 diabetes, but an ENDO 2026 study by Gary Wittert, MBBch, MD, finds these benefits require engagement in a lifestyle program.  More than 40 million people in the U.S. and hundreds of millions worldwide have […]The post VIDEO: Testosterone Alone is Not a Replacement for